Ming-Yue Zhou

Nanomedicine-based targeted strategies for metabolic dysfunction-associated steatotic liver disease: Unraveling pathogenic crosstalk and overcoming clinical barriers.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting approximately one-third of the global adult population, acting as the primary driver of cirrhosis and hepatocellular carcinoma. Despite its growing incidence and substantial clinical and soc...